The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
Repotrectinib is a pill that patients take by mouth. It works by blocking certain proteins that help cancer cells grow and spread. In a clinical trial, repotrectinib shrank tumors in 78% of patients with ROS1 positive NSCLC. Patients who took repotrectinib went about 3 times longer without their disease worsening compared to chemotherapy. The most common side effects of repotrectinib are dizziness, fatigue, dysgeusia (altered sense of taste), constipation, parageusia (distorted sense of taste), diarrhea, nausea, and vomiting. Repotrectinib provides a new targeted therapy option for patients with advanced ROS1 positive NSCLC. More research is still needed to learn about long-term safety and how repotrectinib compares to other ROS1 inhibitors.